Adverse Events with Biomedicines (Record no. 93789)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04120nam a22004335i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-88-470-5313-7 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220082526.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 131209s2014 it | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9788847053137 |
| -- | 978-88-470-5313-7 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-88-470-5313-7 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | R-RZ |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MBGR |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED000000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 610 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Tridente, Giuseppe. |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Adverse Events with Biomedicines |
| Medium | [electronic resource] : |
| Remainder of title | Prevention Through Understanding / |
| Statement of responsibility, etc | by Giuseppe Tridente. |
| 264 #1 - | |
| -- | Milano : |
| -- | Springer Milan : |
| -- | Imprint: Springer, |
| -- | 2014. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | XXX, 633 p. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Part I General Aspects: 1 Introduction -- 2 Adverse drug events to biomedicines -- 3 Systemic syndromes caused by biomedicines -- Part II Monoclonal antibodies: 4 Monoclonal antibodies -- 5 Abciximab -- 6 Adalimumab -- 7 Alemtuzumab -- 8 Basiliximab -- 9 Belimumab -- 10 Bevacizumab -- 11 Brentuximab -- 12 Canakinumab -- 13 Catumaxomab -- 14. Certolizumab -- 15 Cetuximab -- 16 Daclizumab -- 17 Denosumab -- 18 Eculizumab -- 19 Edrecolomab -- 20 Efalizumab -- 21 Gemtuzumab -- 22 Golimumab -- 23 Ibritumomab -- 24 Infliximab -- 25 Ipilimumab -- 26 Muromonab -- 27 Natalizumab -- 28 Nimotuzumab -- 29 Ofatumumab -- 30 Omalizumab -- 31 Palivizumab -- 32 Panitumumab -- 33 Pertuzumab -- 34 Ranibizumab -- 35 Rituximab -- 36 Tocilizumab -- 37 Tositumomab -- 38 Trastuzumab -- 39 Ustekinumab -- Part III Fusion proteins: 40 Fusion proteins -- 41 Abatacept -- 42 Aflibercept -- 43 Alefacept -- 44 Belatacept -- 45 Etanercept -- 46 Rilonacept -- 47 Romiplostim -- Part IV Cytokines : 48 Cytokines -- 49 Interleukins -- 50 Denileukin-diftitox -- 51 Anakinra -- 52 Interferons -- 53 Hemopoietic stimulatory factors -- 54 Myelopoietic stimulatory factors -- 55 Thrombopoietic stimulatory factor -- 56 Pluripotent growth factors -- 57 Epidermal growth factors -- Part V Overview: 58 Biomedicines as adverse event inducers -- 59 Conclusions and perspectives. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicines” – monoclonal antibodies, fusion proteins, and cytokines – that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms of action and immunogenicity in relation to AEs outcome and induction of systemic syndromes. Additional data on AEs in off-label treatments are also considered. Electronic data sheets, downloadable from the Springer Extra Materials platform, include more detailed safety data as well as additional basic information on product characteristics, pre- and post-marketing AEs classified according to frequency, and system/organ targeting. Data on excipients and selected information on drug interactions and associations are also provided. Adverse Events with Biomedicines: Prevention Through Understanding will serve as a detailed, practical guideline to this important new area, which demands the attention of clinicians, immunologists, oncologists, allergologists, public health professionals, and drug companies. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacy. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine general. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine/Public Health, general. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacy. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9788847053120 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-88-470-5313-7 |
| 912 ## - | |
| -- | ZDB-2-SBL |
No items available.